Enhanced Portfolio, Ease of Partnership

Created in 2013 by four European-based pharmaceutical companies, Aggrega Pharma is focused on enhancing
our partners portfolios by providing access to the most attractive generic drug product opportunities.

 

About

Aggrega Pharma is committed to building a selective, valuable pipeline of generic products by leveraging the vast R&D, clinical and manufacturing experience and capabilities of its members.  The shareholders are 4 European companies:

  • Bluepharma (Portugal)

  • Rafarm (Greece)

  • Substipharm (France) 

  • Welding (Germany)

sam-moqadam-2rrsfMN4hn8-unsplash%20(1)_e

Vision

Establish Aggrega Pharma as a premier partner to create a fully integrated pharmaceutical supply chain up to commercialization of drug product.

Science Lab

Strategy

Invest in Aggrega’s internal drug product portfolio through utilizing Aggrega’s global development, financial strength, and scale in sourcing and manufacturing footprint

Partner using flexible commercial models to co-develop
and co-invest in generic drug products and select 505(b)2 opportunities.

Focus initially on US market and appropriately expand
concept ex-US.

Partnership

We are continually looking to expand and increase our finished dose portfolio through collaborative working – a core principle at Aggrega Pharma.

 

Our partnership combines flexible and innovative business models with collaborative process development to strengthen your products, while reducing your risk.

Business Handshake

Our partnership offering is supported by our network of development and commercial manufacturing facilities

at Bluepharma (Portugal) and Rafarm (Greece) as well as our network of finished dose CDMOs in Europe, North America and Asia to meet your global product requirements.

 
 
 
 
n2-01.png
1-01.png

PORTUGAL

download-01.png

GERMANY

3-01.png

FRANCE

4-01.png

GREECE

icones novos_Prancheta 1 cópia.png

Combined Revenue

>$500M/Year

icones novos_Prancheta 1 cópia 2.png

Combined Employees

>1200

icones novos_Prancheta 1 cópia 3.png

Countries

60+

icones novos_Prancheta 1 cópia 4.png

Global Product Launches

100+

1-01.png
download-01.png
3-01.png
4-01.png

Headquarters

Coimbra, Portugal

Hamburg, Germany

Paris, France

Athens, Greece

Founded

2001

1955

1995

1976

Extended and Immediate Release

Oral Solid finished dose development and commercial manufacturing facilities (FDA inspected). Clinical study management expertise through Blueclinical. 

Develop, register, supply

and commercialize drug

products globally with focus

on various dosage forms, incl. niche, complex & high potent.

API sourcing, regulatory affairs & distribution.

Develop, supply

and commercialize

drug products (ex-US) with

focus on niche, complex

dosage forms. 

Sterile Injectable and Ophthalmic finished dose development and commercial manufacturing facilities (FDA inspected).

 

Shareholders

 

Team

ProfSergio_3.jpg

Sérgio Paulo Simões

Board Member

MITSOPOULOS_PHOTO[1].jpg

Aris Mitsopoulos

Board Member

_LFA9533.jpg

Lars Hallmayer

Board Member

Substipharm-858.jpg

Leopold Berthier

Board Member

giulia.jpg

Giulia Falcone

Executive Director

Substipharm-30.jpg

Sylvie Fondanayche

Executive Director

KK.jpg

Simon Knölk

Executive Director

Tobias_profile 2.jpg

Tobias Silva

Executive Director

Head Shot 2019.jpg

Kevin Hennessy

US General Manager

science-in-hd-KxLKiiCl0gA-unsplash.jpg

Portfolio

nova tabela_Prancheta 1.png

* Early Development

 

Latest News

header-about1.jpeg
Bluepharma Group
finishes 2020 with
a growth of over 20%

Bluepharma celebrates

20 years and prepares

a investment of

200 million euros.

Screen Shot 2021-07-04 at 15.34.25.png
Rafarm & 
Upsher-Smith

Upsher-Smith And Rafarm announce launch of Moxifloxacin Ophthalmic Solution, USP 0.5%.

Sem título-2_Prancheta 1.png
CPHI Worldwide Milan

11 November 2021

Fiera Milano, Milan, Italy

 
 

Contact

Get in Touch

Follow Us On:

  • LinkedIn

© 2021 Proudly created with Wix.com

6 Arrow RD, STE 200

Ramsey, New Jersey 07446, USA